US Patent Issued to Aurigene Oncology on June 17 for "Substituted heterocyclyl derivatives as CDK inhibitors" (Indian Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,023, issued on June 17, was assigned to Aurigene Oncology Ltd. (Bangalore, India).

"Substituted heterocyclyl derivatives as CDK inhibitors" was invented by Susanta Samajdar (Bangalore, India), Ramulu Poddutoori (Karimnagar, India), Chetan Pandit (Bangalore, India), Subhendu Mukherjee (Hooghly, India) and Rajeev Goswami (Deharadun, India).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. ...